Carzenide | CAS# 138-41-0 | antispasmodic | dysmenorrhoea

MedKoo Cat#: 412415 | Name: Carzenide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carzenide is an antispasmodic that has been used in the treatment of dysmenorrhoea. Currently Carzenide is an organic synthesis intermediate, used for synthetic drug.

Chemical Structure

Carzenide

CAS#138-41-0 (free base)

Theoretical Analysis

MedKoo Cat#: 412415

Name: Carzenide

CAS#: 138-41-0 (free base)

Chemical Formula: C7H7NO4S

Exact Mass: 201.0096

Molecular Weight: 201.19

Elemental Analysis: C, 41.79; H, 3.51; N, 6.96; O, 31.81; S, 15.93

Price and Availability

Size	Price	Availability
5g	USD 250.00	2 Weeks
10g	USD 350.00	2 Weeks
25g	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

6101-29-7 (sodium) 138-41-0 (free base)

Synonym

Carzenide; BRN1875393; BRN-1875393; BRN 1875393; Carzenidum; Carzenida;

IUPAC/Chemical Name

4-sulfamoylbenzoic acid

InChi Key

UCAGLBKTLXCODC-UHFFFAOYSA-N

InChi Code

InChI=1S/C7H7NO4S/c8-13(11,12)6-3-1-5(2-4-6)7(9)10/h1-4H,(H,9,10)(H2,8,11,12)

SMILES Code

O=C(O)C1=CC=C(S(=O)(N)=O)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 201.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Irshad S, Ahmad S, Khan SU, Khan MA, Ejaz SA, Rao H, Khurshid U, Ahmed A, Shahzad N, Al-Kahtani HM, Waheed A, Wani TA, Aborode AT. Synthesis, biochemical characterization and in silico investigation of 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid derivatives: dual action mode inhibitors of urease and virulent bacterial stains. Biochem J. 2022 Oct 14;479(19):2035-2048. doi: 10.1042/BCJ20220395. PMID: 36111588. 2: Wang X, Feng YL, Zhao XY, An R, Cao C, Guo MB, Zhang R, Wang YX, Hou Z, Guo C. Discovery of novel aminosaccharide-based sulfonamide derivatives as potential carbonic anhydrase II inhibitors. Bioorg Med Chem Lett. 2021 Dec 1;53:128420. doi: 10.1016/j.bmcl.2021.128420. Epub 2021 Oct 30. PMID: 34728369. 3: Shetnev A, Shlenev R, Efimova J, Ivanovskii S, Tarasov A, Petzer A, Petzer JP. 1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B. Bioorg Med Chem Lett. 2019 Nov 1;29(21):126677. doi: 10.1016/j.bmcl.2019.126677. Epub 2019 Sep 10. PMID: 31537422. 4: Corcuera A, Stolle K, Hillmer S, Seitz S, Lee JY, Bartenschlager R, Birkmann A, Urban A. Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro. Antiviral Res. 2018 Oct;158:135-142. doi: 10.1016/j.antiviral.2018.07.011. Epub 2018 Jul 20. PMID: 30031759. 5: Patil R, Fells JI, Szabó E, Lim KG, Norman DD, Balogh A, Patil S, Strobos J, Miller DD, Tigyi GJ. Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor. J Med Chem. 2014 Aug 28;57(16):7136-40. doi: 10.1021/jm5007116. Epub 2014 Aug 12. PMID: 25100502; PMCID: PMC4148159. 6: New bitter blocker discovered, study finds. J Am Dent Assoc. 2011 Aug;142(8):901. doi: 10.14219/jada.archive.2011.0291. PMID: 21919220. 7: Beyer J, Bierl A, Peters FT, Maurer HH. Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation. Ther Drug Monit. 2005 Aug;27(4):509-20. doi: 10.1097/01.ftd.0000160719.96445.91. PMID: 16044110. 8: Ullrich KJ, Fritzsch G, Rumrich G, David C. Polysubstrates: substances that interact with renal contraluminal PAH, sulfate, and NMeN transport: sulfamoyl-, sulfonylurea-, thiazide- and benzeneamino-carboxylate (nicotinate) compounds. J Pharmacol Exp Ther. 1994 May;269(2):684-92. PMID: 8182536. 9: Palfrey HC, Silva P, Epstein FH. Sensitivity of cAMP-stimulated salt secretion in shark rectal gland to "loop" diuretics. Am J Physiol. 1984 Mar;246(3 Pt 1):C242-6. doi: 10.1152/ajpcell.1984.246.3.C242. PMID: 6322593. 10: Eckhardt K, King MT, Gocke E, Wild D. Mutagenicity study of Remsen-Fahlberg saccharin and contaminants. Toxicol Lett. 1980 Nov;7(1):51-60. doi: 10.1016/0378-4274(80)90085-5. PMID: 6794189. 11: Poncelet F, Mercier M, Lederer J. Saccharin: para forms of some impurities are not mutagenic in Salmonella typhimurium. Food Cosmet Toxicol. 1980 Aug;18(4):453. doi: 10.1016/0015-6264(80)90236-9. PMID: 7007186. 12: Nelson JJ. Quantitation of o- and p-sulfamoylbenzoic acids in commerical saccharin by high-performance liquid chromatography. J Assoc Off Anal Chem. 1976 Mar;59(2):243-50. PMID: 1254544. 13: HAMOR GH, JANFAZA M. Synthesis of alkyl esters of 4-amino-2-sulfamoylbenzoic acid. J Pharm Sci. 1963 Jan;52:102-3. doi: 10.1002/jps.2600520126. PMID: 13952427.